FACET BIOTECH CORP Form 8-K February 26, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (date of earliest event reported): February 23, 2010

Facet Biotech Corporation

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)

001-34154 (Commission File No.)

26-3070657 (I.R.S. Employer Identification No.)

1500 Seaport Boulevard Redwood City, California 94063 (Address of principal executive offices)

Registrant s telephone number, including area code: (650) 454-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

0	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
0	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
0	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
O	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Item 2.02 Results of Operations and Financial Condition.

On February 23, 2010, Facet Biotech Corporation issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2009 (the <u>Earnings Release</u>) and conducted a webcast conference call regarding these financial results (the Webcast). The Earnings Release and transcript of the Webcast are attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this current report on Form 8-K and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Exhibit Description
99.1	Press Release dated February 23, 2010 regarding the financial results of Facet Biotech Corporation for the fourth quarter and full year ended December 31, 2009
99.2	Transcript of Webcast conference call held on February 23, 2010 regarding the financial results of Facet Biotech Corporation for the fourth quarter and full year ended December 31, 2009

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 26, 2010 Facet Biotech Corporation

By: /s/ Andrew Guggenhime

Andrew Guggenhime

Senior Vice President and Chief Financial Officer

3